Details
Stereochemistry | EPIMERIC |
Molecular Formula | C16H16ClNO3S.H2O4S |
Molecular Weight | 435.9 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OS(O)(=O)=O.COC(=O)[C@@H](N1CCC2SC(=O)C=C2C1)C3=CC=CC=C3Cl
InChI
InChIKey=UNHVSUGSGIXYQF-LDCKTULKSA-N
InChI=1S/C16H16ClNO3S.H2O4S/c1-21-16(20)15(11-4-2-3-5-12(11)17)18-7-6-13-10(9-18)8-14(19)22-13;1-5(2,3)4/h2-5,8,13,15H,6-7,9H2,1H3;(H2,1,2,3,4)/t13?,15-;/m0./s1
Molecular Formula | C16H16ClNO3S |
Molecular Weight | 337.821 |
Charge | 0 |
Count |
|
Stereochemistry | EPIMERIC |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Molecular Formula | H2O4S |
Molecular Weight | 98.078 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/19122335
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19122335
Clopidogrel is first activated to its thiolactone intermediate, 2-oxo-clopidogrel via CYP3A oxidation. 2-oxo-clopidogrel is a key intermediate metabolite from which the active metabolite is formed. 2-oxo-clopidogrel inhibited the activity of CYP2C19 and moderately activity of CYP2B6.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL3622 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19122335 |
0.995 µM [IC50] | ||
Target ID: CHEMBL4729 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19122335 |
1.3 µM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
PubMed
Title | Date | PubMed |
---|---|---|
Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. | 2010 Jan |
|
Cytochromes P450 catalyze both steps of the major pathway of clopidogrel bioactivation, whereas paraoxonase catalyzes the formation of a minor thiol metabolite isomer. | 2012 Feb 20 |
Patents
Sample Use Guides
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/12386137
2-oxo-clopidogrel (SR121682) is the essential key intermediate metabolite from which the active metabolite is formed. This was approved using enzymatic assay with human liver microsomes. SR121682 was added at a final concentration of 0.1 mM, and the reaction was initiated with 1 mM NADPH
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 14:36:19 GMT 2023
by
admin
on
Sat Dec 16 14:36:19 GMT 2023
|
Record UNII |
R98IO5OIG5
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
R98IO5OIG5
Created by
admin on Sat Dec 16 14:36:19 GMT 2023 , Edited by admin on Sat Dec 16 14:36:19 GMT 2023
|
PRIMARY | |||
|
72206114
Created by
admin on Sat Dec 16 14:36:19 GMT 2023 , Edited by admin on Sat Dec 16 14:36:19 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY | |||
|
ACTIVE MOIETY |